Ready 8-Ks
2
Latest filing
September 8, 2026, 5:10 PM ET
Top materiality
0.85
Event mix
earnings ×1 · other_material ×1
Sentiment
1 pos · 0 neg · 1 neu
Recent 8-K filings for APMD
Highest-materiality recent filing
Apnimed Q2 net income $125.9M on gains; FDA accepts AD109 NDA, PDUFA Feb 28 2027
- Net income $125.9M vs net loss $69.5M year-ago; driven by $85.4M gain on equity-method investment sale and $57.1M deposit liability reversal.
- R&D expenses $9.9M, down 38% YoY ($16.0M); G&A $12.7M, up >100% from $5.4M on commercialization prep.
-
Apnimed Q2 net income $125.9M on gains; FDA accepts AD109 NDA, PDUFA Feb 28 2027
Net income $125.9M vs net loss $69.5M year-ago; driven by $85.4M gain on equity-method investment sale and $57.1M deposit liability reversal.
-
Apnimed adopts amended charter and bylaws upon IPO consummation
Filed ninth amended and restated certificate of incorporation on August 3, 2026, effective with IPO closing.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.68 · Most common event earnings